BRIEF—Chi-Med launches Elunate in China

Chi-Med, a Chinese biopharma company that is majority owned by the conglomerate CK Hutchison Holdings, has launched Elunate (fruquintinib) in China, in collaboration with its launch partner Eli Lilly.

The therapy is approved to treat certain people with metastatic colorectal cancer (CRC) that have been previously treated with chemotherapy.

CRC is the second most common cancer type in China, with about 380,000 new cases per year.

The firm is developing the therapy in multiple further indications, including in combination with other cancer therapies.